RAdx6 Profile

The RAdx6 is a novel comprehensive diagnostic and prognostic panel for rheumatoid arthritis available exclusively at RDL. It combines 4 novel markers (14-3-3n, anti-CEP-1 anti-Sa and anti-CarP) with 2 traditional marker anti-CCP and RF) to not only enhance the diagnosis of RA in early or established disease, but also to help predict disease severity. If 14-3-3n and/or anti-Sa positivity is present, the disappearance or decrease of these antibodies with treatment is associated with less radiographic progression. In pre-clinical RA, positivity of anti-CEP-1 along with anti-CCP antibodies significantly raises the risk of imminently developing clinical RA.

Anti-CarP may predict the development of RA independently of Anti-CCP and may be present years before the onset of symptoms in RA. Anti-CarP may confer a 10% incremental benefit in identify early RA and is associated with more active disease and higher risk of developing joint erosions.

The RAdx6 is a novel comprehensive diagnostic and prognostic panel for rheumatoid arthritis available exclusively at RDL. It combines 4 novel markers (Anti-MCV, anti-CEP-1 anti-Sa and anti-CarP) with 2 traditional marker anti-CCP and RF) to not only enhance the diagnosis of RA in early or established disease, but also to help predict disease severity. If anti-MCV and/or anti-Sa positivity is present, the disappearance or decrease of these antibodies with treatment is associated with less radiographic progression. In pre-clinical RA, positivity of anti-CEP-1 along with anti-CCP antibodies significantly raises the risk of imminently developing clinical RA.

Anti-CarP may predict the development of RA independently of Anti-CCP and may be present years before the onset of symptoms in RA. Anti-CarP may confer a 10% incremental benefit in identifying early RA and is associated with more active disease and higher risk of developing joint erosions.